The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
The World Health Organization has resumed its trial of hydroxychloroquine, after a temporary suspension of the trial for purported safety concerns.
W.H.O’s director general, Tedros Ghebreyesus said at a news conference in Geneva, that the Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug.
Last week, WHO announced suspension of the trial of the drug, popular for the treatment of malaria after a medical journal published that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.
Numerous clinical trials are looking to see if it is effective in fighting Covid-19, but it is not yet a proven treatment.
Related posts:
LASG approves clinical trial of Ivermectin for Covid-19
COVID-19: WHO to commence worldwide clinical trial of three new drugs
COVID-19: WHO suspends Hydroxychloroquine trial
Coronavirus: NAFDAC approves production of Chloroquine for Clinical trial
WHO halts trial of hydroxychloroquine over safety concerns
COVID-19: China approves two vaccines for clinical trials
U.K Scientists begin Clinical trials of COVID-19 Vaccine
Brazil’s Vice President taking Hydroxychloroquine to treat Covid-19
